Shell Awards GATE Energy Sparta Project Commissioning Contract “`

HOUSTON, Dec. 9, 2024 — GATE Energy has been awarded the commissioning contract by Shell Offshore, Inc. for its Sparta semi-submersible project. GATE Energy provides comprehensive project lifecycle support, from design to commissioning, encompassing owner’s engineering, construction management, and turnkey commissioning and startup. Mark Myhre, GATE Energy's President of Commissioning,…

Cominar Redeems 5.95% Series 12 Debentures “`

/NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES/ MONTREAL, December 9, 2024 – Cominar Real Estate Investment Trust (“Cominar” or the “REIT“) today announced the redemption of its 5.95% Series 12 Debentures due May 5, 2025 (the “Debentures“). Cominar will redeem the full outstanding principal…

Vantage Awarded Top Honors for Trust and Corporate Social Responsibility at 2024 Professional Trader Awards “`

LONDON, Dec. 10, 2024 — Multi-asset broker, (or “Vantage”) is pleased to announce it has been recognized as the “Most Trusted Broker” and “Best Corporate Social Responsibility” at the 2024 Professional Trader Awards. These awards highlight Vantage's dedication to dependable trading services and positive global community impact. Vantage is especially…

New Tool Automates Sanctions Screening for Compliancy Group Clients “`

NEW YORK, December 10, 2024 — Compliancy Group has launched an automated employee and vendor sanction screening tool for monitoring and verifying exclusion lists. This release follows Compliancy Group’s recent partnership with SureShield, integrating their automated sanctions and exclusions software into Compliancy Group’s compliance platform, The Guard. This combined solution…

Jacobio Pharma Presents Early-Stage Myelofibrosis Data for BET Inhibitor at ASH 2024 “`

BEIJING, SHANGHAI and BOSTON, December 8, 2024 — Jacobio Pharma (1167.HK), a clinical-stage oncology company specializing in developing therapies targeting previously undruggable targets, today announced preliminary Phase I data for its BET inhibitor, JAB-8263, in the treatment of myelofibrosis (MF) at the 2024 ASH (American Society of Hematology) Annual Meeting…